I've been writing about this stuff in a few past posts. And I want to bring some fresh awareness on it.
Julianna LeMieux, Senior Fellow in Molecular Biology, wrote an update on the website of the American Council on Science and Health, about the approval of the first gene therapy for cancer in the U.S.
The therapy uses a drug called Kymriah, developed by Novartis, for the treatment of B-cell acute lymphoblastic leukemia (ALL) in children and young adults. This type of therapy is put under the umbrella of immunotherapy, which receives a lot of attention in cancer research these days.
One of the reasons for the approval of Kymriah is its efficacy - a remission rate of 83% in 63 patients who've been treated for 3 months. However, there are life-threatening side effects for this type of therapy; and to overcome this issue, to alleviate these side-effects, another drug's approval has been expanded.
I'd recommend reading the full briefing on this by accessing the link below:
To stay in touch with me, follow 
Cristi Vlad, Self-Experimenter and Author